| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 10725 | 2021 |
| Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery M Liong, J Lu, M Kovochich, T Xia, SG Ruehm, AE Nel, F Tamanoi, JI Zink ACS nano 2 (5), 889-896, 2008 | 2214 | 2008 |
| Biocompatibility, biodistribution, and drug‐delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals J Lu, M Liong, Z Li, JI Zink, F Tamanoi Small 6 (16), 1794-1805, 2010 | 1208 | 2010 |
| Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs J Lu, M Liong, JI Zink, F Tamanoi small 3 (8), 1341-1346, 2007 | 1196 | 2007 |
| Light-activated nanoimpeller-controlled drug release in cancer cells J Lu, E Choi, F Tamanoi, JI Zink Small (Weinheim an der Bergstrasse, Germany) 4 (4), 421, 2008 | 506 | 2008 |
| Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation S Awale, J Lu, SK Kalauni, Y Kurashima, Y Tezuka, S Kadota, H Esumi Cancer research 66 (3), 1751-1757, 2006 | 434 | 2006 |
| Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells C Hom, J Lu, M Liong, H Luo, Z Li, JI Zink, F Tamanoi Small (Weinheim an der Bergstrasse, Germany) 6 (11), 1185, 2010 | 274 | 2010 |
| Synthesis of biomolecule‐modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells DP Ferris, J Lu, C Gothard, R Yanes, CR Thomas, JC Olsen, JF Stoddart, ... Small 7 (13), 1816-1826, 2011 | 271 | 2011 |
| Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy H Mekaru, J Lu, F Tamanoi Advanced drug delivery reviews 95, 40-49, 2015 | 268 | 2015 |
| In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification J Lu, Z Li, JI Zink, F Tamanoi Nanomedicine: Nanotechnology, Biology and Medicine 8 (2), 212-220, 2012 | 266 | 2012 |
| Mesoporous silica nanoparticles for cancer therapy: energy-dependent cellular uptake and delivery of paclitaxel to cancer cells J Lu, M Liong, S Sherman, T Xia, M Kovochich, AE Nel, JI Zink, F Tamanoi Nanobiotechnology 3, 89-95, 2007 | 231 | 2007 |
| Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein A Suzuki, G Kusakai, A Kishimoto, J Lu, T Ogura, MF Lavin, H Esumi Journal of Biological Chemistry 278 (1), 48-53, 2003 | 188 | 2003 |
| Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging JG Croissant, D Zhang, S Alsaiari, J Lu, L Deng, F Tamanoi, AM AlMalik, ... Journal of Controlled Release 229, 183-191, 2016 | 169 | 2016 |
| ARK5 is a tumor invasion-associated factor downstream of Akt signaling A Suzuki, J Lu, G Kusakai, A Kishimoto, T Ogura, H Esumi Molecular and cellular biology 24 (8), 3526-3535, 2004 | 167 | 2004 |
| Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of drug delivery effect by exocytosis inhibition RE Yanes, D Tarn, AA Hwang, DP Ferris, S Sherman, CR Thomas, J Lu, ... Small (Weinheim an der Bergstrasse, Germany) 9 (5), 697, 2013 | 164 | 2013 |
| Antitumor activity of pyrvinium pamoate, 6‐(dimethylamino)‐2‐[2‐(2,5‐dimethyl‐1‐phenyl‐1H‐pyrrol‐3‐yl)ethenyl]‐1‐methyl‐quinolinium pamoate salt, showing … H Esumi, J Lu, Y Kurashima, T Hanaoka Cancer science 95 (8), 685-690, 2004 | 148 | 2004 |
| Two‐Photon‐Triggered Drug Delivery via Fluorescent Nanovalves J Croissant, A Chaix, O Mongin, M Wang, S Clément, L Raehm, ... Small 10 (9), 1752-1755, 2014 | 127 | 2014 |
| ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation A Suzuki, G Kusakai, A Kishimoto, J Lu, T Ogura, H Esumi Oncogene 22 (40), 6177-6182, 2003 | 127 | 2003 |
| Kigamicin D, a novel anticancer agent based on a new anti‐austerity strategy targeting cancer cells' tolerance to nutrient starvation J Lu, S Kunimoto, Y Yamazaki, M Kaminishi, H Esumi Cancer science 95 (6), 547-552, 2004 | 124 | 2004 |
| Critical illness due to 2009 A/H1N1 influenza in pregnant and postpartum women: population based cohort study TAI Investigators, AMOS System The BMJ 340, 2010 | 121 | 2010 |
